Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus (Q35842621)

10 August 2017

1 reference

title

Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus (English)

1 reference

10 August 2017

1 reference

vaccinia virus

1 reference

Steve H Thorne

1

1 reference

PubMed ID

15268664

10 August 2017

David H Kirn

series ordinal

2

1 reference

PubMed ID

15268664

10 August 2017

language of work or name

English

0 references

publication date

1 August 2004

1 reference

Expert Opinion on Biological Therapy

10 August 2017

1 reference

10 August 2017

4

1 reference

10 August 2017

1307-1321

1 reference

10 August 2017

8

1 reference

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

10 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Oncolytic herpes simplex virus vectors for cancer virotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

RNA viruses as virotherapy agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Intergeneric poliovirus recombinants for the treatment of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Reovirus therapy of tumors with activated Ras pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

NYVAC: a highly attenuated strain of vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Immunisation with canarypox virus expressing rabies glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Expression of cytokines by recombinant vaccinia viruses: a model for studying cytokines in virus infections in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

A phase I trial of intralesional rV-Tricom vaccine in the treatment of malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

An antigenic difference between intracellular and extracellular rabbitpox virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Inactivated Smallpox Vaccine: Immunogenicity of Inactivated Intracellular and Extracellular Vaccinia Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

IMMUNOGENICITY OF ULTRAVIOLET-IRRADIATED, NON-INFECTIOUS, VACCINIA-VIRUS VACCINE IN INFANTS AND YOUNG CHILDREN

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Neutralizing and protective antibodies directed against vaccinia virus envelope antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Modulation of chemokines by poxvirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

A soluble chemokine-binding protein from vaccinia virus reduces virus virulence and the inflammatory response to infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Vaccinia virus blocks gamma interferon signal transduction: viral VH1 phosphatase reverses Stat1 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Orthopoxvirus IL-18 binding proteins: affinities and antagonist activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Vaccinia virus homologues of the Shope fibroma virus inverted terminal repeat proteins and a discontinuous ORF related to the tumor necrosis factor receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Steroid hormone synthesis by vaccinia virus suppresses the inflammatory response to infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Regulation of angiogenesis by hypoxic stress: from solid tumours to the ovarian follicle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Introduction of foreign DNA into the vaccinia virus genome by in vitro ligation: recombination-independent selectable cloning vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Cell proliferative response to vaccinia virus is mediated by VGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Expression of a functional single chain antibody on the surface of extracellular enveloped vaccinia virus as a step towards selective tumour cell targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Bioluminescent indicators in living mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

A conditionally replicating adenovirus targeted to tumor cells through activated RAS/P-MAPK-selective mRNA stabilization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Insertion sites for recombinant vaccinia virus construction: effects on expression of a foreign protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Cidofovir in the treatment of poxvirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

VITILIGO IN A CASE OF VACCINIA VIRUS-TREATED MELANOMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Use of Vaccinia Virus in the Treatment of Metastatic Malignant Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

Ectromelia, vaccinia and cowpox viruses encode secreted interleukin-18-binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1307

10.1517/14712598.4.8.1307

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference

PubMed ID

15268664